With the hope of achieving precision medicine, researchers have applied molecular biotechnology (defined by mRNA expression of 50 genes (PAM50) (Pu et al., 2020)) to classify BC into four molecular subtypes: luminal A, luminal B, basal-like (triple-negative), and HER2-enriched. Here, ERBB2 is linked to breast cancer.